Last updated: September 2, 2026
Lemborexant, marketed as Dayvigo by Eisai, is an FDA-approved dual orexin receptor antagonist for insomnia. Its commercial trajectory is positive but remains smaller than that of established sedative-hypnotics and is increasingly exposed to competition from suvorexant, daridorexant, generic products, and payer restrictions. Eisai’s strategy depends on expanding Dayvigo internationally, increasing prescribing in sleep-maintenance insomnia, and differentiating the product from benzodiazepines and Z-drugs on mechanism and abuse-profile grounds.
Dayvigo received U.S. approval in December 2019 and launched in 2020. The product is approved in the United States at 5 mg and 10 mg doses. Its key commercial protections include five-year new chemical entity exclusivity, Orange Book-listed patent protection, regulatory labeling differentiation, and Eisai’s clinical and commercial position in the dual orexin receptor antagonist class.
What is lemborexant and how does Dayvigo work?
Lemborexant is a small-molecule antagonist of the orexin OX1 and OX2 receptors. Orexin signaling promotes wakefulness. Blocking both receptors reduces wake drive and supports sleep initiation and sleep maintenance.
The drug is indicated for adults with insomnia characterized by difficulties with sleep onset or sleep maintenance. The FDA-approved dosage is 5 mg once nightly, with an option to increase to 10 mg when clinically appropriate. Dayvigo is a Schedule IV controlled substance in the United States.[1]
| Attribute |
Dayvigo |
| Active ingredient |
Lemborexant |
| Manufacturer |
Eisai Co., Ltd. |
| U.S. approval |
Dec. 20, 2019 |
| U.S. launch |
2020 |
| Drug class |
Dual orexin receptor antagonist |
| U.S. doses |
5 mg and 10 mg |
| Indication |
Adult insomnia involving sleep onset or maintenance |
| Controlled-substance schedule |
Schedule IV |
| Primary competitors |
Belsomra, Quviviq, generic sedative-hypnotics |
| Core commercial differentiation |
Sleep-maintenance efficacy and orexin-based mechanism |
Clinical development included the SUNRISE-1 and SUNRISE-2 trials. The studies evaluated sleep onset and sleep maintenance measures using both objective and subjective endpoints. Eisai has positioned lemborexant particularly around reducing wakefulness after sleep onset, a segment where many conventional insomnia therapies have limitations.[1,2]
How large is the lemborexant market?
The addressable market is the global prescription insomnia market, which includes branded and generic sedative-hypnotics, antidepressants used off label, melatonin products, cognitive behavioral therapy, and newer orexin antagonists.
The commercial opportunity is substantial because insomnia is prevalent and chronic treatment is common. The revenue pool is constrained by several factors:
- Generic zolpidem and other low-cost products dominate prescriptions.
- Many patients are treated with nonprescription products or behavioral therapy.
- Payers often require generic failure before covering branded orexin antagonists.
- Insomnia treatment is frequently discontinued because of tolerability, cost, or inadequate perceived benefit.
- Primary-care physicians may remain more familiar with older sedative-hypnotics.
The orexin antagonist segment is expanding from a low base. Belsomra, marketed by Merck, established the class commercially before Dayvigo. Quviviq, developed by Idorsia and commercialized in the United States by Idorsia Pharmaceuticals and later supported through licensing and commercialization arrangements, increased competitive pressure after its approval in 2022.
How does Dayvigo compare with Belsomra and Quviviq?
| Product |
Active ingredient |
Sponsor or commercial partner |
U.S. approval |
Mechanism |
Main competitive issue |
| Dayvigo |
Lemborexant |
Eisai |
2019 |
OX1/OX2 antagonist |
Payer access and generic competition |
| Belsomra |
Suvorexant |
Merck |
2014 |
OX1/OX2 antagonist |
Earlier market entry and established awareness |
| Quviviq |
Daridorexant |
Idorsia |
2022 |
OX1/OX2 antagonist |
Newer label and commercial differentiation |
| Ambien and generics |
Zolpidem |
Multiple generic manufacturers |
1992 |
GABA-A modulation |
Low price and broad prescribing base |
Dayvigo competes most directly with Belsomra and Quviviq. The products have similar mechanisms but differ in pharmacokinetic profiles, clinical trial designs, labeling details, promotional claims, and payer positioning.
Eisai has emphasized Dayvigo’s effect on sleep maintenance and its clinical data in older adults. Quviviq has promoted a shorter half-life and potential next-day functioning advantages. Belsomra benefits from being the first approved dual orexin antagonist but faces a longer period of market exposure and generic-entry pressure in some jurisdictions.
What is the financial trajectory for Dayvigo?
Dayvigo has been one of Eisai’s growth products outside the company’s oncology portfolio. Eisai’s annual reports have shown increasing sales as the product expands across Japan, the United States, and other markets.[3-5]
Publicly reported sales have generally followed this pattern:
| Fiscal period |
Reported commercial direction |
| 2020 |
Initial U.S. launch and limited early uptake |
| 2021 |
Expansion in the United States and Japan |
| 2022 |
Continued growth as prescriber familiarity increased |
| 2023 |
Higher global sales supported by international expansion |
| 2024 and beyond |
Continued growth expected, subject to payer access and competitive pressure |
Eisai reports product sales in Japanese yen and fiscal-year periods ending March 31. Dayvigo has grown from a launch-stage product into a meaningful specialty prescription franchise, but it remains materially smaller than Leqembi, Lenvima, or other major Eisai products.
The financial model has several positive characteristics:
- Manufacturing costs for a small-molecule tablet are generally lower than for biologics.
- The drug does not require infusion infrastructure or specialty pharmacy distribution.
- Insomnia is a large diagnosis category with recurring prescription demand.
- International approvals create opportunities for lifecycle revenue after U.S. growth moderates.
- A dual-receptor mechanism gives Eisai a distinct promotional platform.
The main constraints are lower net pricing than specialty medicines, high generic substitution in the category, and the need for sustained physician promotion. Dayvigo’s revenue growth is therefore likely to decelerate before patent expiry if branded competition intensifies or payers favor lower-cost alternatives.
When does lemborexant lose regulatory exclusivity?
Dayvigo received five-year U.S. new chemical entity exclusivity when the FDA approved lemborexant on Dec. 20, 2019. That exclusivity period expired in December 2024.[1,6]
NCE exclusivity prevented the FDA from accepting an abbreviated new drug application containing the same active ingredient during the protected period, subject to statutory exceptions. The end of NCE exclusivity does not itself authorize generic marketing. Generic applicants still need FDA approval and must address any listed patents.
Other regulatory protections can include pediatric exclusivity, orphan-drug exclusivity, qualified infectious-disease exclusivity, or approval-based protections for specific formulations. These do not appear to be the primary commercial protection for Dayvigo.
What patents protect lemborexant?
Dayvigo’s U.S. patent position is based on patents covering the lemborexant compound, pharmaceutical compositions, and potentially related methods or solid forms. The relevant patent portfolio originates from Eisai research and includes U.S. and international family members.
The commercial patent questions are:
- Whether the core compound patent remains enforceable.
- Whether an Orange Book-listed patent covers the approved product directly.
- Whether later patents cover crystalline forms, formulations, or manufacturing processes.
- Whether generic applicants can avoid infringement through alternative processes or formulations.
- Whether any patent term extension or patent-term adjustment changes the effective expiry date.
The core patent estate is more important than NCE exclusivity because it can delay generic approval or launch beyond 2024. Patent expiry dates should be confirmed against the current FDA Orange Book and the USPTO patent records because listed patents, terminal disclaimers, patent-term adjustments, and regulatory patent-term extensions can alter the effective date.[6,7]
What formulations are protected by the Dayvigo patent estate?
The commercial product is an immediate-release oral tablet containing lemborexant at 5 mg or 10 mg. Relevant protection may include:
- The active lemborexant molecule.
- Oral pharmaceutical compositions.
- Tablet formulations.
- Specific solid-state or crystalline forms.
- Manufacturing and purification processes.
- Methods of treating insomnia.
A generic manufacturer may challenge one or more claims while still seeking approval for a tablet with the same active ingredient. Formulation and process patents can therefore add litigation leverage even when the core compound patent approaches expiry.
Are there Paragraph IV challenges to Dayvigo?
The principal generic pathway is an ANDA containing a Paragraph IV certification against one or more Orange Book-listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed.
A first-filer may qualify for 180 days of generic exclusivity if statutory conditions are satisfied. A Paragraph IV notice can trigger patent litigation, and a timely infringement action can impose a 30-month stay on FDA approval, subject to statutory exceptions.[8]
Publicly available FDA and court records should be used to determine whether an ANDA applicant has issued a Paragraph IV notice for Dayvigo and whether Eisai has filed an infringement action. The commercial significance of a challenge depends on:
- The patent claims cited in the certification.
- Whether Eisai sues within the statutory period.
- The strength of the invalidity and noninfringement arguments.
- The presence of additional unchallenged patents.
- The applicant’s ability to launch “at risk” before final patent resolution.
No publicly established settlement terms should be treated as confirmed without an executed court filing, FDA record, or company disclosure.
What is the Orange Book status of Dayvigo?
The Orange Book is the controlling FDA source for listed patents and exclusivity data for approved small-molecule drugs. Dayvigo’s Orange Book record should be reviewed by reference to:
- Product name: DAYVIGO.
- Active ingredient: lemborexant.
- Dosage forms: tablets.
- Strengths: 5 mg and 10 mg.
- Listed patents and expiry dates.
- Pediatric exclusivity or other regulatory exclusivity codes.
- Any changes to patent listings made by Eisai.
The Orange Book status determines the practical timing of ANDA approval, but it does not eliminate the possibility of patent litigation, at-risk launch, or post-approval enforcement.
How strong is the lemborexant patent estate?
The estate is commercially meaningful but not unassailable. Its strength depends on the remaining life and validity of the core compound claims.
| Factor |
Assessment |
| Core molecule protection |
Highest-value protection |
| NCE exclusivity |
Expired in December 2024 |
| Formulation protection |
Potential secondary barrier |
| Method-of-use protection |
Relevant to insomnia treatment claims |
| Manufacturing protection |
Can complicate generic development |
| Biosimilar protection |
Not applicable |
| Generic substitution risk |
Increasing after NCE expiry |
| Litigation leverage |
Depends on listed patent scope and remaining term |
The estate is stronger if the core patent has a later effective expiry and weaker if generic applicants can design around secondary patents. A tablet product has fewer manufacturing barriers than an injectable or extended-release platform, so process and formulation claims are unlikely to provide indefinite protection by themselves.
Does lemborexant face biosimilar risk?
No. Lemborexant is a synthetic small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.
Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence. They do not need to repeat the full clinical efficacy program, which materially reduces development cost and accelerates competitive entry after regulatory and patent barriers fall.
What licensing deals affect Dayvigo?
Eisai retains the central commercial role for Dayvigo. International commercialization can involve regional subsidiaries, local affiliates, distribution partners, or country-specific licensing arrangements. The material commercial question is whether Eisai transfers rights in a territory and whether the partner bears development, regulatory, or promotional costs.
Unlike products built around a broad co-commercialization network, Dayvigo’s value remains closely tied to Eisai’s own commercial execution. Any regional license should be evaluated for:
- Territory.
- Upfront payment and milestones.
- Royalty rate.
- Supply obligations.
- Minimum purchase commitments.
- Development responsibilities.
- Termination rights.
- Control of patent enforcement.
No transaction should be treated as a global Dayvigo license unless the agreement covers the product across major markets.
What litigation affects lemborexant?
Patent litigation is the principal legal risk for Dayvigo once ANDA applicants begin challenging listed patents. Potential disputes may involve:
- Infringement of compound patents.
- Validity of composition-of-matter claims.
- Obviousness and written-description defenses.
- Patent-term calculations.
- Formulation and polymorph claims.
- Induced infringement based on generic labeling.
- Settlement restrictions under the Hatch-Waxman framework.
A litigation-driven launch date can differ materially from the nominal patent expiry date. Settlement agreements can permit entry before expiry, while an unsuccessful Paragraph IV challenge can defer entry until patent expiration or a negotiated date.
What generic launch scenarios exist for Dayvigo?
| Scenario |
Commercial timing |
Likely impact |
| No ANDA challenge |
After patent expiry |
Gradual generic entry |
| Paragraph IV settlement |
Negotiated date |
Predictable but earlier erosion |
| Successful Paragraph IV challenge |
Before listed expiry |
Rapid price and share pressure |
| At-risk launch |
Before final judgment |
High litigation exposure for generic |
| Multiple generic entrants |
After first launch |
Steep net-price erosion |
| Authorized generic |
During settlement or post-expiry |
Greater control for Eisai but lower branded volume |
The most damaging scenario for Eisai is an early successful Paragraph IV challenge followed by multiple generic launches. A negotiated entry date would reduce legal uncertainty but still compress the product’s terminal value.
What is the FDA regulatory status of Dayvigo?
Dayvigo is FDA approved for adult insomnia. Its label includes warnings regarding central nervous system depression, next-day impairment, complex sleep behaviors, worsening depression or suicidal ideation, sleep paralysis, hypnagogic or hypnopompic hallucinations, and compromised respiratory function in susceptible patients.[1]
The drug is contraindicated in patients with narcolepsy. Concomitant use with strong or moderate CYP3A inhibitors can increase lemborexant exposure and requires attention to dosing and labeling restrictions.
Regulatory risk is lower than for a new molecular entity in active development because the product has an established safety database. The main regulatory exposure is postmarketing safety, controlled-substance oversight, and any label changes affecting prescribing.
Key Takeaways
- Lemborexant is Eisai’s dual orexin antagonist marketed as Dayvigo.
- U.S. approval occurred on Dec. 20, 2019, and NCE exclusivity expired in December 2024.
- Revenue growth has been supported by expansion in the United States, Japan, and other international markets.
- The main commercial competitors are Belsomra, Quviviq, and inexpensive generic sedative-hypnotics.
- Dayvigo is a small molecule, so biosimilar risk does not apply. ANDA-based generic risk does.
- The core patent estate and any formulation, method-of-use, or manufacturing patents determine generic timing.
- Payer restrictions and physician familiarity remain material barriers to faster adoption.
- The largest financial risk is a successful Paragraph IV challenge followed by rapid multi-generic entry.
- Dayvigo’s long-term value depends on international expansion, class growth, pricing durability, and the effective expiry of its Orange Book-listed patents.
FAQs
Is lemborexant the same as suvorexant?
No. Lemborexant is marketed as Dayvigo, while suvorexant is marketed as Belsomra. Both block OX1 and OX2 orexin receptors but are different chemical entities.
Is Dayvigo a controlled substance?
Yes. The FDA classifies lemborexant as a Schedule IV controlled substance in the United States.
Can a generic version of Dayvigo launch after December 2024?
Not automatically. NCE exclusivity expired in December 2024, but FDA approval and any remaining Orange Book patent barriers still govern generic launch.
Is lemborexant protected by orphan-drug exclusivity?
No orphan-drug exclusivity is the primary commercial protection for Dayvigo. Its key protections are NCE exclusivity and patent rights.
Which company owns Dayvigo?
Eisai developed and markets Dayvigo. Regional commercialization may involve Eisai affiliates or local partners, but Eisai is the principal rights holder and sponsor.
References
- U.S. Food and Drug Administration. (2019). Dayvigo: Prescribing information. https://www.accessdata.fda.gov
- Eisai Co., Ltd. (2019). Eisai announces FDA approval of Dayvigo (lemborexant) for the treatment of insomnia. https://www.eisai.com
- Eisai Co., Ltd. (2023). Annual report and financial results. https://www.eisai.com
- Eisai Co., Ltd. (2024). Financial results and corporate reporting. https://www.eisai.com
- Eisai Co., Ltd. (2024). Integrated report. https://www.eisai.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs
- U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and Paragraph IV certifications. https://www.fda.gov/drugs
